

APPENDIX 1. Inhalers for COPD.

RESPTREC®
RESPIRATORY TRAINING
& EDUCATOR COURSE

COPD MEDICATIONS

www.resptrec.org
www.lung.ca

Short-Acting Bronchodilators

SAMA

(Short-Acting Muscarinic Antagonist)
USE REGULARLY or PRN



Atrivent® MDI
(ipratropium bromide)
20 mcg/dose
Duration: 4-6h
Company: BI
*nebulas also available

SABA

(Short-Acting Beta2-Agonist)
USE REGULARLY or PRN
*RESCUE MEDICATION



Airmir® MDI
(salbutamol sulphate)
100 mcg/dose
Duration: 24h
Company: Valeant

Additional Medications

Oral Corticosteroid (OCS):
Prednisone (Apotex, Teva, Jaapharm, Pro Doc Ltée)

Methylxanthines:
(e.g. theophylline, oxtriphylline, etc.)

Phosphodiesterase-4 inhibitor:
Daxas® (roflumilast) (Takeda)

Company Key:

AZ - AstraZeneca Canada Inc
BI - Boehringer Ingelheim (Canada) Ltd
GSK - GlaxoSmithKline Inc
Novartis - Novartis Pharmaceuticals Canada Inc
Takeda - Takeda Canada Inc.
Valeant - Valeant Canada

Dose = one inhalation
MDI = Metered Dose Inhaler

* Maximize drug delivery & decrease side effects by using a valved-holding chamber with a metered-dose inhaler

* Video instructions found at: www.sk.lung.ca/devices
* Product information found at: www.sk.lung.ca/drugs
* Detailed information on the drugs can be found on the Canada Product Database at: <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
* Additional RESPREC resources and most current electronic versions available at: www.sk.lung.ca/resptrec-resources
* Note: may not be a complete list of COPD medications

BREATHE
the lung association

Long-Acting Bronchodilators

LAMA


(Long-Acting Muscarinic Antagonist)
USE REGULARLY



Incruse® Ellipta®
(umeclidinium bromide)
62.5 mcg/dose
Duration: 24h
Company: GSK

LABA

(Long-Acting Beta2-Agonist)
USE REGULARLY



Foradil® Aerolizer®
(formoterol fumarate)
12 mcg/dose
Duration: 12h
Company: Novartis



Seebri® Breezhaler®
(glycopyrronium bromide)
50 mcg/dose
Duration: 24h
Company: Novartis




Onbrez® Breezhaler®
(indacaterol maleate)
75 mcg/dose
Duration: 24h
Company: Novartis



Spiriva® Handihaler®
(tiotropium bromide monohydrate)
18 mcg/dose
Duration: 24h
Company: BI



Serevent® Diskus®
(salmeterol xinafoate) 50 mcg/dose
Duration: 12h
Company: GSK



Spiriva® Respimat®
(tiotropium bromide monohydrate)
2.5 mcg/dose
Duration: 24h
Company: BI



Striverdi® Respimat®
(olodaterol hydrochloride)
2.5 mcg/dose
Duration: 24h
Company: BI
*Approved by Health Canada but may not be available yet



Tudorza® Genuair®
(acridinium bromide)
400 mcg/dose
Duration: 12h
Company: AZ

Combination Inhalers

ICS/LABA

(Inhaled Corticosteroid/Long-Acting Beta2-Agonist)
USE REGULARLY
*Gargle and spit after each use



Advair® Diskus®
(fluticasone propionate/
salmeterol xinafoate)
100/50; 250/50; 500/50 mcg
doses
Duration: 12h
Company: GSK
*only the Advair® Diskus® has been
approved for COPD use.




Breo® Ellipta®
(fluticasone furoate/
vilanterol trifenate)
100/25 mcg/dose
Duration: 24h
Company: GSK




Symbicort® Turbuhaler®
(budesonide/formoterol fumarate)
100/6; 200/6; 400/12 FORTE
mcg doses
Duration: 12h
Company: AZ

ICS/LAMA/LABA

USE REGULARLY



Trelegy® Ellipta®
(fluticasone furoate/
umeclidinium bromide/
vilanterol trifenate)
100/62.5/25 mcg/dose
Duration: 24h
Company: GSK



Combivent® Respimat®
(ipratropium bromide/salbutamol
sulphate)
20/100 mcg/dose
Duration: 4-6h
Company: BI
*nebulas also available



Anoro® Ellipta®
(umeclidinium bromide/vilanterol
trifenate)
62.5/25 mcg/dose
Duration: 24h
Company: GSK



Duaklir® Genuair®
(acridinium bromide/formoterol
fumarate dehydrate)
400/12 mcg/dose
Duration: 12h
Company: AZ



Inspilo® Respimat®
(tiotropium bromide
monohydrate/olodaterol
hydrochloride)
2.5/2.5 mcg dose
Duration: 24h
Company: BI



Ultibro® Breezhaler®
(glycopyrronium bromide/
indacaterol maleate)
50/110 mcg/dose
Duration: 24h
Company: Novartis

LAMA and LABA

USE REGULARLY

Permission is granted to copy the document as is. Images in this document are copyrighted and may not be reproduced.

© Copyright 2017

© The Foundation for Medical Practice Education, www.fmpe.org

May 2019

